Baxter buys Baxa for $380M; FDA says no to migraine patch;

> Baxter International ($BAX) has agreed to pay $380 million for Baxa, which develops pharmacy technology for oral and IV dose preparation and delivery. The deal is designed to enhance Baxter's nutrition and drug-delivery business. Item | Release

> FDA says no to NuPathe's Zelrix migraine patch. Article

> Drug-eluting balloons in long infrapopliteal arteries could be safe and effective, but more clinical trials are necessary to prove their worth. Story

> Drug delivery patent application of the week: Modified polysaccarides for drug and contrast agent delivery. Patent application

Suggested Articles

Purdue's reformulated OxyContin may stop patients from snorting or injecting the drug, but it doesn't curb abuse overall, an FDA panel determined.

Roche is gearing up to launch an eye implant to make its Lucentis AMD drug easier to use. But the drugmaker has even bigger plans for the device.

Delivery specialist IntelGenx struck two deals to develop oral films for prescription psychedelics this summer with Canada's Cybin and ATAI.